No Data
No Data
Express News | Kiora Pharmaceuticals Shares Are Trading Higher After the Company Announced That It Will Present Additional Data From Its ABACUS-1 Trial of KIO-301 in Retinitis Pigmentosa at the ARVO 2024 Annual Meeting
Analysts Offer Insights on Healthcare Companies: Altimmune (ALT), Kiora Pharmaceuticals (KPRX) and Actinium Pharmaceuticals (ATNM)
Express News | Kiora Pharmaceuticals to Present Additional Data From Its ABACUS-1 Trial Of KIO-301 in Retinitis Pigmentosa At ARVO 2024 Annual Meeting
Kiora Pharmaceuticals to Present Additional Data From Its ABACUS-1 Trial in Retinitis Pigmentosa at the ARVO 2024 Annual Meeting
Encinitas, California--(Newsfile Corp. - March 28, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") announced that additional data from the ABACUS-1 trial has been accept
Kiora Pharmaceuticals Price Target Maintained With a $2.00/Share by HC Wainwright & Co.
Kiora Pharmaceuticals Price Target Maintained With a $2.00/Share by HC Wainwright & Co.
Analysts Offer Insights on Healthcare Companies: Kiora Pharmaceuticals (KPRX) and Genmab (GMAB)
No Data